Mesure de l'incidence de l'hépatite virale B selon la séroconversion pour l'AC HBC, chez les donneurs de sang du Québec
|Authors:||Traoré, Aïcha Nina|
|Advisor:||Germain, Marc; Maunsell, Elizabeth|
|Abstract:||The goal of this study was to evaluate the residual risk of hepatitis B viral (HBV) by measuring its incidence among 112,242 blood donors at Hema-Quebec, via the seroconversion for the antibody directed against the core (anti-HBc) instead of the usual surface antigen (HBsAg). We considered as incident cases donors who had a seroconversion for the anti-HBc and who were screened positive for the anti-HBs (antibody directed against the HBsAg). From April 2003 to April 2005, the identification of 13 anti-HBc incident cases and 3 for HBsAg permitted us to estimate respective incidences of 12.6 x 105 person-years-1 and 3.35 x 105 person-years-1, which corresponded to residual risks of 1 in 63,018 donations and 1 in 237,731 donations. The HBV incidence via the anti-HBc seroconversion is different from the estimate via the HBsAg. Our study suggests that anti-HBc seroconversion may not be a reliable marker of recent hepatitis B infection.|
|Document Type:||Mémoire de maîtrise|
|Open Access Date:||12 April 2018|
|Collection:||Thèses et mémoires|
All documents in CorpusUL are protected by Copyright Act of Canada.